These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-II). Pepine CJ; Lopez LM; Bell DM; Handberg-Thurmond EM; Marks RG; McGorray S J Am Coll Cardiol; 1997 Oct; 30(4):955-61. PubMed ID: 9316524 [TBL] [Abstract][Full Text] [Related]
8. Antianginal effects of nitroglycerin patches. Reichek N; Priest C; Zimrin D; Chandler T; Sutton MS Am J Cardiol; 1984 Jul; 54(1):1-7. PubMed ID: 6430053 [TBL] [Abstract][Full Text] [Related]
9. Prevention of vascular nitroglycerin tolerance by inhibition of protein kinase C. Zierhut W; Ball HA Br J Pharmacol; 1996 Sep; 119(1):3-5. PubMed ID: 8872349 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and rebound phenomenon related to intermittent nitroglycerin therapy for the prevention of nitrate tolerance. Watanabe H; Kakihana M; Ohtsuka S; Sugishita Y Jpn Circ J; 1998 Aug; 62(8):571-5. PubMed ID: 9741733 [TBL] [Abstract][Full Text] [Related]
11. Regional and systemic hemodynamic and humoral effects of transdermal nitroglycerin in mild hypertension. Pedrinelli R; Graziadei L; Panarace G; Duranti P; Motolese M; Salvetti A J Cardiovasc Pharmacol; 1989 Oct; 14(4):636-41. PubMed ID: 2478778 [TBL] [Abstract][Full Text] [Related]
12. Hemodynamic attenuation and the nitrate-free interval: alternative dosing strategies for transdermal nitroglycerin. Flaherty JT Am J Cardiol; 1985 Dec; 56(17):32I-37I. PubMed ID: 3000161 [TBL] [Abstract][Full Text] [Related]
13. [The noninvasive quantitative evaluation of the acute hemodynamic effects of sublingual and transdermal nitroglycerin in man]. Pizzetti F; Peci P; Manni B; Bonaglia M; Ghio S; Latini R; Avanzini F G Ital Cardiol; 1993 Apr; 23(4):327-34. PubMed ID: 8319860 [TBL] [Abstract][Full Text] [Related]
14. Effects of sublingual nitroglycerin in patients receiving transdermal nitroglycerin for coronary artery disease: prevention of cross-tolerance. Naito H; Matsuda Y; Yorozu T; Shiomi K; Maeda T; Seki K; Tada T; Fujii H Clin Cardiol; 1991 Aug; 14(8):644-50. PubMed ID: 1914267 [TBL] [Abstract][Full Text] [Related]
15. Nitroglycerin-induced relaxation of anorectal smooth muscle: evidence for apparent lack of tolerance development in the anaesthetized rat. Wang EQ; Soda DM; Fung HL Br J Pharmacol; 2001 Sep; 134(2):418-24. PubMed ID: 11564661 [TBL] [Abstract][Full Text] [Related]
16. Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production. Probes with inhibitors and tolerance development. Chung SJ; Fung HL Biochem Pharmacol; 1993 Jan; 45(1):157-63. PubMed ID: 8424809 [TBL] [Abstract][Full Text] [Related]
17. Nitroglycerin in chronic stable angina pectoris. Reichek N Am J Cardiol; 1987 Nov; 60(15):15H-17H. PubMed ID: 3120561 [TBL] [Abstract][Full Text] [Related]
18. Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use. Todd PA; Goa KL; Langtry HD Drugs; 1990 Dec; 40(6):880-902. PubMed ID: 2127741 [TBL] [Abstract][Full Text] [Related]
19. Rapid development of nitrate tolerance in healthy volunteers: assessment using spectral analysis of short-term blood pressure and heart rate variability. Cloarec-Blanchard L; Funck-Brentano C; Carayon A; Jaillon P J Cardiovasc Pharmacol; 1994 Aug; 24(2):266-73. PubMed ID: 7526059 [TBL] [Abstract][Full Text] [Related]
20. Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance. Hill M; Takano H; Tang XL; Kodani E; Shirk G; Bolli R Circulation; 2001 Aug; 104(6):694-9. PubMed ID: 11489777 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]